CompletedPhase 4

Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor

France2,459 participantsStarted 2020-01-17

Plain-language summary

The purpose of this study is to measure the impact of a discontinuous administration of oxytocin during the active phase of the 1st stage of labor on the neonatal morbidity rate. The investigators hypothesize that discontinuation of oxytocin in the active phase of labor (from 6 cm) in women who received oxytocin in the latent phase or for an induction (before 4 cm of dilation) could reduce neonatal morbidity.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * With a term (≥37 WG) pregnancy * Singleton pregnancy * Fetus in cephalic presentation * Women receiving oxytocin during the latent phase of the 1st stage of labor, before 4 cm of cervical dilatation, including women with an induction of labor using cervical ripening or oxytocin * Speaking and reading French language * Affiliated to social security * Who have signed the consent form Exclusion Criteria: * Women with a scarred uterus * Fetus with a congenital anomaly * Fetal growth retardation \<3rd percentile * Having an abnormal fetal heart rate at randomization * Maternal age \< 18 years * Participating in another trial involving medication

What they're measuring

neonatal morbidity composite measure

Timeframe: At birth

Trial details

NCT IDNCT03991091

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04-25

View on ClinicalTrials.gov More Neonatal Morbidity trials